MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 20, 2026Sponsor estimate | NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial Neoplasms | MRKLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 20, 2026Sponsor estimatePhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT02644369Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsUniversity Health Network, Toronto · Squamous Cell Cancer of Head and NeckActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 4NCT04206813An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination RegimenBoston Medical Center · HPV InfectionActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center · Adenoid Cystic CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04417166Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · Lymphoma, Extranodal NK-T-CellActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05082259ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabInstitute of Cancer Research, United Kingdom · Advanced CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT05378425A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With PembrolizumabNectin Therapeutics Ltd · CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT05467917ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index CasesColumbia University · COVID-19Active, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05977907Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Head and Neck Squamous Cell CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimatePhase 1NCT07776665A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2NCT06066957Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsUniversity of Pennsylvania · Cytomegalovirus InfectionsActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07748351A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)Merck Sharp & Dohme LLC · HealthyActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimatePhase 1/Phase 2NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell...Merck Sharp & Dohme LLC · Renal Cell CarcinomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center · Uterine CarcinosarcomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT03362060PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerMassachusetts General Hospital · Triple Negative Breast CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT04699123The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerYale University · Advanced Non-small Cell Lung CancerActive, not recruitingNXTCCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT04707248A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsDaiichi Sankyo · Renal Cell CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT03383094Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerLoren Mell, MD · Head and Neck Squamous Cell CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04184050Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Multiple Myeloma in RelapseActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT04255849Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIVWeill Medical College of Cornell University · HPV Positive Oropharyngeal Squamous Cell CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT04919122Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaDuke University · Metastatic Renal Cell CarcinomaActive, not recruitingEXELCollaboratorBMYCollaboratorPFECollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05286437Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleNational Cancer Centre, Singapore · Hormone Receptor-Positive HER2-Negative Advanced Breast CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT02658279Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeMemorial Sloan Kettering Cancer Center · Glioma | MRKCollaborator | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT03694158Investigating Dupilumab's Effect in Asthma by GenotypeBoston Children's Hospital · Asthma | SNYCollaboratorMRKCollaboratorREGNCollaborator | Phase 4 | Active, not recruiting | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT04666740A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination...Memorial Sloan Kettering Cancer Center · Metastatic Pancreatic Ductal Adenocarcinoma | MRKCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT02658279Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeMemorial Sloan Kettering Cancer Center · GliomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 4NCT03694158Investigating Dupilumab's Effect in Asthma by GenotypeBoston Children's Hospital · AsthmaActive, not recruitingSNYCollaboratorMRKCollaboratorREGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT04666740A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination...Memorial Sloan Kettering Cancer Center · Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 13 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.